Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes

Starting soon · Phase 2

Conditions studied: Myelodysplastic Syndromes (MDS), Anemia

In brief

This study is a prospective, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of dapagliflozin in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS). Anemia is the most common clinical problem in patients with lower-risk MDS and often leads to fatigue, reduced quality of life, and the need for repeated blood transfusions. Current treatment options, including erythropoiesis-stimulating agents and other therapies, are not effective in all patients, and additional treatment options are needed. Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that is widely used for the treatment of diabetes, heart failure, and chronic kidney disease. Previous studies have shown that SGLT2 inhibitors can increase hemoglobin levels, possibly by stimulating erythropoiesis. In this study, eligible patients will receive dapagliflozin 10 mg orally once daily for 24 weeks. The primary objective is to evaluate the hemoglobin response rate during the study period. Secondary objectives include changes in hemoglobin levels, transfusion requirements, and safety outcomes. This study aims to explore whether dapagliflozin can serve as a potential treatment option for anemia in patients with lower-risk MDS.

Key facts

Study ID

NCT07516847

Run by

Seug yun Yoon, MD

People needed

37

Starts

2026-09-01

Expected to finish

2029-09-01

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged ≥18 years
• Diagnosis of myelodysplastic syndromes (MDS) according to WHO or ICC criteria
• Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate risk
• Hemoglobin ≤10 g/dL at screening
• Transfusion independent or low transfusion burden (Defined as ≤2 units of red blood cell transfusion within 8 weeks prior to enrollment)
• If receiving erythropoiesis-stimulating agents (ESA) or other anemia-directed therapy, on a stable dose for at least 8 weeks prior to enrollment
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Absolute neutrophil count (ANC) ≥0.75 ×10⁹/L
• Platelet count ≥50 ×10⁹/L
• Adequate organ function:
• Creatinine clearance ≥30 mL/min AST or ALT ≤3 × upper limit of normal

You may not qualify if…

• IPSS-R intermediate-high or high-risk MDS
• Transformation to acute myeloid leukemia or ≥20% blasts
• Initiation or dose change of MDS- or anemia-directed therapy (e.g., ESA, luspatercept, hypomethylating agents) within 8 weeks prior to screening
• Red blood cell transfusion >2 units within 8 weeks prior to enrollment
• Current use of SGLT2 inhibitors or history of serious adverse reaction to SGLT2 inhibitors
• Uncontrolled diabetes mellitus (e.g., HbA1c >10%) or history of diabetic ketoacidosis
• Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²
• Active or uncontrolled infection
• Absolute neutrophil count (ANC) <0.75 ×10⁹/L or platelet count <50 ×10⁹/L
• Pregnant or breastfeeding women
• Any condition that, in the investigator's judgment, would make participation inappropriate

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.